PE84099A1 - Derivados de bencimidazol - Google Patents

Derivados de bencimidazol

Info

Publication number
PE84099A1
PE84099A1 PE1998000488A PE00048898A PE84099A1 PE 84099 A1 PE84099 A1 PE 84099A1 PE 1998000488 A PE1998000488 A PE 1998000488A PE 00048898 A PE00048898 A PE 00048898A PE 84099 A1 PE84099 A1 PE 84099A1
Authority
PE
Peru
Prior art keywords
halogen
hydroxy
compound
alkyl
bencimidazole
Prior art date
Application number
PE1998000488A
Other languages
English (en)
Inventor
David Norman Deaton
John Charles Drach
Jr Frank Leslie Boyd
Marc W Andersen
George Andrew Freeman
Stanley Dawes Chamberlain
Leroy B Townsend
Susan Mary Daluge
Original Assignee
Univ Michigan
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711982.0A external-priority patent/GB9711982D0/en
Priority claimed from GBGB9714552.8A external-priority patent/GB9714552D0/en
Application filed by Univ Michigan, Glaxo Group Ltd filed Critical Univ Michigan
Publication of PE84099A1 publication Critical patent/PE84099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 ES HALOGENO, HIDROXI, AZIDO, ENTRE OTROS; R2 ES H o HALOGENO; R3 Y R4 SON H, HALOGENO, ALQUILO C1-C8, ENTRE OTROS; Z ES UN GRUPO DE FORMULA (Ia, Ib, Ic); R5 ES H, ALQUILO C1-C8, HALO-ALQUILO C1-C8, ALCOXI C1-C8; R6 ES H, HIDROXI, HALOGENO, ENTRE OTROS; R7 ES H, HIDROXI, HALOGENO, ENTRE OTROS o R6 Y R7 FORMAN JUNTOS UNA CETONA O ALQUENO; R8-R11 SON H, HIDROXI, HALOGENO, ENTRE OTROS; R12-R18 SON H, HIDROXI, ALQUILO C1-C8; CON LA CONDICION QUE EL COMPUESTO NO PUEDE SER 2,5-DIMETIL-1-(2,3,4-TRI-O-ACETIL-BETA-D-XILOPIRANOSIL)-1H-BENCIMIDAZOL o 5,6-DIMETIL-1-(2,3,4-TRI-O-ACETIL-BETA-D-ARABINOPIRANOSIL)-BENCIMIDAZOL-2-TIONA, ENTRE OTRAS CONDICIONES. TAMBIEN SE REFIERE A UN COMPUESTO DE FORMULA II. UN COMPUESTO PREFERIDO ES (3S,4R,5R,6S)-2-BROMO-5,6-DICLORO-1-(TETRAHIDRO-4,5-DIHIDROXI-6-(HIDROXIMETIL)-2H-PIRAN-3-IL)-1H-BENCIMIDAZOL. EL COMPUESTO I PUEDE SER UTIL PARA LA PROFILAXIS O TRATAMIENTO DE UNA INFECCION POR VIRUS DEL HERPES, POR CITOMEGALOVIRUS, VIRUS DE LA HEPATITIS B
PE1998000488A 1997-06-10 1998-06-09 Derivados de bencimidazol PE84099A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711982.0A GB9711982D0 (en) 1997-06-10 1997-06-10 Benzimidazole derivatives
GBGB9714552.8A GB9714552D0 (en) 1997-07-11 1997-07-11 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
PE84099A1 true PE84099A1 (es) 1999-09-24

Family

ID=26311687

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000488A PE84099A1 (es) 1997-06-10 1998-06-09 Derivados de bencimidazol

Country Status (35)

Country Link
US (1) US6455507B1 (es)
EP (1) EP0994890B1 (es)
JP (1) JP4548866B2 (es)
KR (1) KR20010020465A (es)
CN (1) CN1265665A (es)
AP (1) AP1262A (es)
AR (1) AR012964A1 (es)
AT (1) ATE246700T1 (es)
AU (1) AU740792C (es)
BR (1) BR9810745A (es)
CA (1) CA2293470C (es)
CO (1) CO4970737A1 (es)
DE (1) DE69816992T2 (es)
DK (1) DK0994890T3 (es)
EA (1) EA002305B1 (es)
EE (1) EE9900564A (es)
ES (1) ES2205527T3 (es)
HK (1) HK1024921A1 (es)
HR (1) HRP980303B1 (es)
HU (1) HUP0002224A3 (es)
ID (1) ID24054A (es)
IL (1) IL133285A0 (es)
IS (1) IS5285A (es)
MA (1) MA26504A1 (es)
MY (1) MY132872A (es)
NO (1) NO314847B1 (es)
NZ (1) NZ501415A (es)
OA (1) OA11230A (es)
PE (1) PE84099A1 (es)
PL (1) PL337773A1 (es)
PT (1) PT994890E (es)
SK (1) SK171499A3 (es)
TR (1) TR199903053T2 (es)
TW (1) TW565566B (es)
WO (1) WO1998056761A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027205A1 (en) 1996-01-23 1997-07-31 The Regents Of The University Of Michigan Imidazo[1,2-a]pyridine c-nucleosides as antiviral agents
CN1272113A (zh) 1997-07-30 2000-11-01 密歇根大学董事会 作为抗病毒剂的来苏呋喃糖基苯并咪唑类化合物
DE19741715A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
DK1368028T3 (da) 2001-03-12 2007-12-27 Avanir Pharmaceuticals Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2004261663A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
WO2005049582A1 (en) * 2003-11-14 2005-06-02 Auspex Pharmaceuticals, Inc. Method of preparation of novel nucleoside analogs and uses
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
DE102005019549A1 (de) * 2005-04-25 2006-12-14 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
US7989422B2 (en) * 2005-12-22 2011-08-02 Alchemia Limited Antibacterial agents
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
EP2188298B1 (en) 2007-08-15 2013-09-18 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2009100045A1 (en) * 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2010036613A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2012507530A (ja) 2008-10-29 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
EP2393825A2 (en) 2009-02-06 2011-12-14 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
US9382294B2 (en) 2013-03-01 2016-07-05 Los Alamos National Security, Llc Broad spectrum antibiotic compounds and use thereof
EP3647318B1 (en) 2014-04-28 2021-06-30 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US10077242B2 (en) * 2014-12-01 2018-09-18 Virginia Commonwealth University Convergent approach to the total synthesis of telmisartan via a suzuki cross-coupling reaction
RU2629670C2 (ru) * 2016-08-04 2017-08-31 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) 2-Амино-5,6-дифтор-1-(бета-D-рибофуранозил)-бензимидазол, способ получения и противовирусная активность его в отношении вируса герпеса простого 1-го типа
KR102583547B1 (ko) 2020-03-30 2023-10-06 (주)바이오메트릭스 테크놀로지 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도
EP3907230A1 (en) 2020-03-30 2021-11-10 Biometrix Technology Inc. Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same
CN114096549A (zh) * 2020-06-23 2022-02-25 博美利克斯技术公司 新型苯并咪唑衍生物、其制备方法及其作为抗癌剂或者抗病毒剂的用途
KR102449266B1 (ko) 2020-06-23 2022-09-30 (주)바이오메트릭스 테크놀로지 항암 활성 그리고 항바이러스 활성을 갖는 신규한 벤지미다졸-탄수화물 결합체 화합물(Benzimidazole carbohydrate conjugate compound) 및 이의 제조 방법
KR102342313B1 (ko) 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1491244A (fr) 1966-03-09 1967-08-11 Nouveaux benzimidazoles solubles
FR1476350A (fr) 1966-04-18 1967-04-07 Yale & Towne G M B H Ferme-porte automatique à frein
US3655901A (en) 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
DE2130030A1 (de) 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
EP0304624A3 (de) 1987-07-29 1989-03-22 F. Hoffmann-La Roche Ag Benzimidazol-2-yl-pyridiniumverbindungen
IT1226100B (it) 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
AU5447094A (en) 1992-10-21 1994-05-09 Regents Of The University Of Michigan, The Polysubstituted benzimidazoles as antiviral agents
US5399580A (en) 1993-03-08 1995-03-21 Burroughs Wellcome Co. Therapeutic nucleosides-uses
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
AU8536098A (en) 1998-12-30
KR20010020465A (ko) 2001-03-15
SK171499A3 (en) 2000-08-14
EA199901031A1 (ru) 2000-06-26
EA002305B1 (ru) 2002-02-28
NO314847B1 (no) 2003-06-02
CN1265665A (zh) 2000-09-06
MY132872A (en) 2007-10-31
CA2293470C (en) 2008-05-13
NO996086D0 (no) 1999-12-09
AP1262A (en) 2004-03-16
OA11230A (en) 2003-07-09
AU740792B2 (en) 2001-11-15
PT994890E (pt) 2003-11-28
DE69816992T2 (de) 2004-07-22
ATE246700T1 (de) 2003-08-15
AR012964A1 (es) 2000-11-22
DE69816992D1 (en) 2003-09-11
HUP0002224A3 (en) 2003-05-28
US6455507B1 (en) 2002-09-24
IL133285A0 (en) 2001-04-30
NZ501415A (en) 2001-10-26
AU740792C (en) 2003-01-23
ES2205527T3 (es) 2004-05-01
TR199903053T2 (xx) 2000-11-21
DK0994890T3 (da) 2003-12-01
JP2002504105A (ja) 2002-02-05
EP0994890B1 (en) 2003-08-06
HRP980303B1 (en) 2002-08-31
AP9901707A0 (en) 1999-12-31
EE9900564A (et) 2000-06-15
HRP980303A2 (en) 1999-04-30
HK1024921A1 (en) 2000-10-27
US20020094963A1 (en) 2002-07-18
CA2293470A1 (en) 1998-12-17
BR9810745A (pt) 2001-03-13
WO1998056761A2 (en) 1998-12-17
TW565566B (en) 2003-12-11
PL337773A1 (en) 2000-09-11
MA26504A1 (fr) 2004-12-20
CO4970737A1 (es) 2000-11-07
NO996086L (no) 2000-02-09
HUP0002224A1 (hu) 2001-04-28
IS5285A (is) 1999-12-06
EP0994890A2 (en) 2000-04-26
WO1998056761A3 (en) 1999-04-15
JP4548866B2 (ja) 2010-09-22
ID24054A (id) 2000-07-06

Similar Documents

Publication Publication Date Title
PE84099A1 (es) Derivados de bencimidazol
ID1018B (id) N-tersier-butil-dekahidro-2(3-amino-2-hidroksi-4-fenil-butil) isokinolin-3-karboksamida dan turunan-turunan asparaginil darinya
KR890004709A (ko) 항원충제로서의 아지트로마이신 및 이의 유도체
PE1398A1 (es) Compuestos de bencilaminopiperidina sustituidos
DE3684299D1 (de) Neuartige verwendung von taurolin.
FR2654617B1 (fr) Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux.
RU94037553A (ru) Солерастворимые неорганические волокна, применение их в качестве огнеупорной изоляции, способ изготовления огнеупорной изоляции
DE69325944D1 (de) s-Triazinderivate als Lichtschutzmittel
NO954161L (no) 10,11-metandibenzosuberanderivater for anvendelse som kjemosensibiliserende midler
FI873631A0 (fi) --alkyl-4-amino-3-kinolinmetanoler och 1-(4-aralkylamino-3-kinolinyl)alkanoler, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
FI902555A0 (fi) Diarylstyrylkinolindisyror.
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
PE79599A1 (es) Derivados de 5'-desoxicitidina
DE69023960D1 (de) Phenylalkan(en)säuren.
PT89120A (pt) Processo para a preparacao de novos derivados flavonoides 2-piperazinil-2-oxo-etileno substituidos
SE8301924L (sv) Substituerade penem-derivat och forfarande for framstellning derav
DK291390A (da) Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
NO164352C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive, antivirale, substituerte isoksazolderivater.
ES2092645T3 (es) Metanoantracenos como antagonistas de dopamina.
KR880007528A (ko) [3s(z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류
BR9407533A (pt) Composto para a proteção de um vertebrado contra a infecção por helmintos composição na forma de uma vacina processo para causar uma resposta imunológica aos helmintos em um vertebrado e produto de reação
FI903950A0 (fi) Ny komposition.
SE8700566D0 (sv) Tetracyclic quinazolinones
ECSP951499A (es) Compuestos ariltios
TH14131EX (th) นิวคลีโอไซด์ ซึ่งมีสรรพคุณทางบำบัดรักษา

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed